Medical Weight Loss
Clinic in San Ramon, CA

Ozempic® and Wegovy® are both brand names for semaglutide. Ozempic (up to 2.0 mg weekly) is FDA-approved for type 2 diabetes; Wegovy (up to 2.4 mg weekly, also now available as a daily pill) is FDA-approved for chronic weight management. At MedLounge San Ramon, our providers evaluate your health history and goals to determine the right semaglutide dosing strategy for you. Both injectable and oral options may be available. Book a free consultation to discuss which form is right for your lifestyle.

Semaglutide (Wegovy, Ozempic) activates the GLP-1 receptor — reducing appetite, slowing digestion, and averaging 14.9% body weight loss over 68 weeks. Tirzepatide (Zepbound, Mounjaro) activates both GLP-1 and GIP receptors, producing stronger appetite suppression and greater fat metabolism improvements, averaging 20–25% body weight loss. The 2025 SURMOUNT-5 head-to-head trial confirmed tirzepatide's superiority over semaglutide for weight loss. The right choice depends on your health history, tolerance, and goals — which is why we evaluate every patient individually.

Program costs at MedLounge San Ramon vary based on the medication (semaglutide, tirzepatide, or retatrutide), your starting dose, and your personalized treatment plan. Doses are gradually increased over time, so monthly costs can change as your program progresses. We provide full transparent pricing during your initial consultation — no surprises. Most clients find that in-clinic, physician-guided care delivers better long-term value than online subscription programs because of the dose optimization, accountability, and side-effect management included. We also accept direct-pay without insurance approval, making the process faster and more flexible.

Most clients begin noticing reduced appetite within the first 1–2 weeks. Visible weight loss typically starts within the first month and becomes more consistent between weeks 4–12 as your dose is optimized. On average, clients lose 1–3 pounds per week when following their recommended lifestyle modifications. Clinical data shows average weight loss of around 15% with semaglutide and 20–25% with tirzepatide over 36–88 weeks at full doses. Individual results depend on starting weight, adherence, lifestyle factors, and dose titration — which is why our San Ramon providers monitor your progress at every visit and adjust your plan accordingly.

This is an important question. The FDA has issued specific warnings about compounded and unapproved versions of semaglutide and tirzepatide, noting reports of serious adverse events, dosing errors, and fraudulent products with falsified pharmacy information. Compounded medications do not undergo FDA review for safety, effectiveness, or quality. At MedLounge San Ramon, we prescribe only through proper medical evaluation, use licensed pharmacy sources, and monitor your response in person — which is what separates responsible in-clinic prescribing from mail-order or telehealth-only programs where oversight is limited.

Weight regain is a real consideration when stopping GLP-1 therapy, because these medications work as long as you take them — the appetite-regulating effects reduce once discontinued. At MedLounge San Ramon, we address this proactively through a structured maintenance phase. Options include gradually tapering to the lowest effective dose, transitioning to lifestyle-based weight management, or continuing low-dose maintenance therapy to sustain results. We also provide ongoing nutrition guidance focused on protein intake, metabolic habits, and sustainable eating patterns that reduce the risk of regain after stopping medication.

No. MedLounge San Ramon operates on a direct-pay basis, meaning you do not need insurance approval to begin treatment. Many clients prefer this model because it eliminates prior authorization delays and lets our providers prescribe based on your actual medical needs rather than insurance criteria. We provide full pricing transparency during your consultation. While some insurance plans may cover branded medications like Wegovy or Zepbound, coverage varies widely and is not required to access our program.

Yes, and it's a common and generally safe transition when done under medical supervision. Some clients start on semaglutide and later move to tirzepatide for stronger appetite suppression or greater weight loss potential — particularly if progress has plateaued or they want the added metabolic benefits of the dual GLP-1/GIP mechanism. Our San Ramon providers evaluate your current dose, response, side-effect history, and goals before recommending any medication change. Switching is never done arbitrarily — it's a clinical decision based on your individual progress.

Switching from Ozempic (semaglutide) to Mounjaro or Zepbound (tirzepatide) is generally safe and medically straightforward when done under provider supervision. Many patients switch because tirzepatide produces greater weight loss. Switching from Ozempic to Mounjaro or Zepbound — the 2025 SURMOUNT-5 trial confirmed tirzepatide is superior to semaglutide head-to-head. At MedLounge San Ramon, our providers evaluate your current dose, side effect history, and weight loss progress before recommending a switch. The transition typically involves a brief washout or overlap period depending on your current dose. Never switch GLP-1 medications without provider guidance.